Pacira BioSciences, Inc.
PCRX
$25.99
$0.632.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.73% | 1.08% | 3.32% | 2.83% | 5.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.73% | 1.08% | 3.32% | 2.83% | 5.05% |
| Cost of Revenue | -6.31% | -25.75% | -5.02% | -4.31% | -7.49% |
| Gross Profit | 4.54% | 12.28% | 8.22% | 7.02% | 10.29% |
| SG&A Expenses | 30.02% | 20.48% | 20.99% | 9.40% | 5.05% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.95% | 5.98% | 7.09% | 2.64% | 0.58% |
| Operating Income | -70.51% | -48.22% | -13.05% | 4.14% | 33.15% |
| Income Before Tax | -105.27% | -36.17% | -24.30% | -936.43% | -3.35% |
| Income Tax Expenses | -83.50% | -16.46% | 7.18% | -19.73% | 46.37% |
| Earnings from Continuing Operations | -125.66% | -46.41% | -35.50% | -1,421.29% | -26.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.66% | -46.41% | -35.50% | -1,421.29% | -26.69% |
| EBIT | -70.51% | -48.22% | -13.05% | 4.14% | 33.15% |
| EBITDA | -26.85% | -13.56% | -3.19% | 6.82% | 17.77% |
| EPS Basic | -126.06% | -46.14% | -35.14% | -1,429.54% | -26.83% |
| Normalized Basic EPS | -104.13% | -33.32% | -11.56% | 14.07% | 49.48% |
| EPS Diluted | -128.29% | -47.84% | -38.14% | -1,462.24% | -24.46% |
| Normalized Diluted EPS | -104.53% | -25.52% | -6.64% | 27.92% | 54.24% |
| Average Basic Shares Outstanding | -1.55% | -0.48% | -0.57% | -0.61% | 0.19% |
| Average Diluted Shares Outstanding | -10.05% | -10.86% | -5.82% | -11.39% | -2.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |